Kamada Ltd. (KMDA) to Issue Annual Dividend of $0.17 on September 17th

Kamada Ltd. (NASDAQ:KMDA) announced an annual dividend on Monday, August 17th. Stockholders of record on Thursday, August 27th will be given a dividend of 0.17 per share by the biotechnology company on Thursday, September 17th. This represents a dividend yield of 219.0%. The ex-dividend date of this dividend is Thursday, August 27th.

Kamada has a dividend payout ratio of 30.8% meaning its dividend is sufficiently covered by earnings. Equities research analysts expect Kamada to earn $0.60 per share next year, which means the company should continue to be able to cover its $0.12 annual dividend with an expected future payout ratio of 20.0%.

Kamada Price Performance

Kamada stock opened at $8.43 on Tuesday. The company has a market capitalization of $484.77 million, a PE ratio of 22.18, a price-to-earnings-growth ratio of 0.67 and a beta of 0.86. Kamada has a one year low of $6.50 and a one year high of $9.35. The business has a 50 day simple moving average of $7.31 and a 200 day simple moving average of $7.94.

Kamada (NASDAQ:KMDA) last announced its quarterly earnings results on Wednesday, August 12th. The biotechnology company reported $0.16 EPS for the quarter, beating the consensus estimate of $0.11 by $0.05. Kamada had a return on equity of 8.37% and a net margin of 11.60%.The business had revenue of $54.92 million for the quarter, compared to analyst estimates of $50.84 million. Equities analysts anticipate that Kamada will post 0.49 earnings per share for the current fiscal year.

Kamada Company Profile

Kamada Ltd. is a biopharmaceutical company headquartered in Israel that specializes in the development, manufacturing and commercialization of plasma‐derived protein therapeutics. The company focuses on treatments for rare and serious diseases, leveraging its proprietary fractionation and purification technologies to produce purified human proteins. Kamada’s product portfolio addresses critical therapeutic areas in immunology, hematology and pulmonology, where alternative treatment options may be limited.

Among Kamada’s marketed products is Glassia®, an alpha‐1 antitrypsin augmentation therapy approved by the U.S.